CL King Downgrades Pacific Biosciences of California (PACB) to Neutral
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Price: $1.35 +9.76%
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
CL King downgraded Pacific Biosciences of California (NASDAQ: PACB) from Buy to Neutral.
Analyst Dave Westenberg steps aside citing valuation as the stock reached his PT.
For an analyst ratings summary and ratings history on Pacific Biosciences of California click here. For more ratings news on Pacific Biosciences of California click here.
Shares of Pacific Biosciences of California closed at $5.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- UBS Upgrades Apollo Tyres (APTY:IN) to Buy
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
CL KingSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
